Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 2003 Aug;71(8):4717–4723. doi: 10.1128/IAI.71.8.4717-4723.2003

SCID Mouse Model for Lethal Q Fever

Masako Andoh 1, Takashi Naganawa 1, Akitoyo Hotta 1, Tsuyoshi Yamaguchi 1, Hideto Fukushi 1,*, Toshiaki Masegi 2, Katsuya Hirai 1
PMCID: PMC166031  PMID: 12874353

Abstract

Q fever, a worldwide zoonosis caused by Coxiella burnetii, has many manifestations in humans. Endocarditis is the most serious complication of Q fever. Animal models are limited to acute pulmonary or hepatic disease and reproductive disorders. An appropriate experimental animal model for Q fever endocarditis does not yet exist. In this study, severe combined immunodeficient (SCID) mice infected with C. burnetii showed persistent clinical symptoms and died, whereas immunocompetent mice similarly infected became asymptomatic and survived. The SCID mice examined in this study had severe chronic lesions in their primary organs: the heart, lung, spleen, liver, and kidney. The heart lesions of the SCID mice were similar to those in humans with chronic Q fever endocarditis: they had focal calcification and expanded macrophages containing C. burnetii. The 50% lethal dose of C. burnetii in SCID mice was at least 108 times less than that in immunocompetent mice. The SCID mouse is highly susceptible to C. burnetii, and the immunodeficiency of the host enhances the severity of Q fever. This animal model could provide a new tool for the study of chronic Q fever and Q fever in immunodeficient hosts.


Q fever is a worldwide zoonosis caused by an obligate intracellular bacterium, Coxiella burnetii. The disease in humans typically has both an acute form and a chronic form. Acute Q fever is a flu-like illness which is self-limiting and easily treated with antibiotics when an appropriate diagnosis is made. Chronic Q fever is usually manifested as endocarditis or vascular infection. Endocarditis is the most serious complication of Q fever because the treatment is difficult and the mortality is high (9). Naturally infected animals rarely demonstrate illness except for reproductive disorders, such as abortion. Guinea pigs and mice are used as laboratory animal models for acute Q fever, but they require a high dose of inoculum. The A/J strain of mice, which is immunocompetent, is the strain that is most susceptible to C. burnetii (25). Immunosuppressive treatments of various experimental animals have been reported to raise their susceptibility to C. burnetii (1, 11, 26, 27).

The pathogenesis of the disease is little known because research on chronic Q fever has been limited to clinical case studies. An appropriate animal model for the study of chronic Q fever and its antibiotic therapy does not yet exist. Patients with Q fever endocarditis are known to have histories of heart valve damage or to lack an appropriate immune response. Several animal models for Q fever endocarditis have been proposed, but the clinical signs differ from those in human cases. Endocarditis in guinea pigs with previous valvular damage after C. burnetii infection was only transient (15). BALB/c mice that were physiologically immunosuppressed by repeated pregnancy for 2 years after C. burnetii infection (28) developed endocarditis with fibrin deposits, a generic sign of chronic lesions, but the incidence of endocarditis was low (2 out of 13 mice). BALB/c mice that underwent cyclophosphamide treatment after C. burnetii infection developed endocarditis, but the cases were transient (1). A suitable, more sensitive animal model is needed to clarify the pathogenicity of chronic Q fever.

The severe combined immunodeficient (SCID) mouse has no functional T and B cells (6, 8). It is highly susceptible to various pathogens that have low pathogenicity for immunocompetent animals. In the present study, we compared the clinical symptoms, the histopathology, and the survival rates of C. burnetii infection in SCID mice and immunocompetent mice to determine whether the SCID mouse could be used as an animal model for chronic Q fever. This is the first report of persistent C. burnetii infection in an animal that resulted in severe chronic lesions and death.

MATERIALS AND METHODS

Mice.

SCID (C.B-17/Icr-scid/scid) mice and immunocompetent C.B-17 (C.B-17/Icr-+/+) mice were obtained from Japan CLEA Inc. (Tokyo, Japan). A/J mice were obtained from Japan SLC Inc. (Shizuoka, Japan). Five- to 6-week-old female mice were used in the experiments. They were housed under sterile conditions at all times. All procedures were done under the guidelines for animal experiments at Gifu University.

Microorganism.

The Nine Mile I strain of C. burnetii was maintained in mice by passage in spleen homogenates. The spleen homogenates were prepared in sucrose phosphate glutamate, kept at −80°C, and diluted with phosphate-buffered saline (PBS). C. burnetii in the homogenate was titrated to the 50% tissue culture infectious dose (TCID50) in buffalo green monkey (BGM) cells by the indirect immunoperoxidase method (24).

Inoculation of mice and clinical studies.

To compare the pathogenicities of C. burnetii in immunodeficient and immunocompetent mice, SCID mice (n = 11), C.B-17 mice (n = 6), and A/J mice (n = 6) were inoculated intraperitoneally with 10 TCID50 of C. burnetii. As controls, SCID mice (n = 10), C.B-17 mice (n = 6), and A/J mice (n = 6) were mock inoculated with PBS. The mice were observed for 37 days, which is the time at which the last C. burnetii-infected mouse died. To compare the dose responses of the immunodeficient and immunocompetent mice, SCID mice (n = 6) were inoculated intraperitoneally with 0.5 ml of serial 10-fold dilutions (104 to 10−5 TCID50) of C. burnetii. C.B-17 mice (n = 6) were similarly inoculated with 10-fold dilutions (104 to 10−3 TCID50) of C. burnetii. As controls, SCID mice (n = 6) and C.B-17 mice (n = 6) were mock inoculated with PBS. The SCID mice were observed for 60 days, and the C.B-17 mice were observed for 30 days. The 50% lethal dose (LD50) was calculated by the Behrens-Kärber method (5). Clinical signs and body weight were recorded daily. Relative body weight is the weight on a given day divided by the body weight on the day of inoculation. Blood samples were obtained by puncture of the heart under anesthesia before euthanasia. At necropsy, the spleen and liver were weighed, and a part of each organ was stored at −80°C. The rest of the spleen and liver and the heart, lungs, and kidneys were preserved in 10% formalin PBS.

Histopathology and immunocytochemistry.

The organs of the mice that received 10 TCID50 of C. burnetii and the control mice were examined. Sections of paraffin-embedded organs were prepared and stained with hematoxylin and eosin. The distribution of C. burnetii was examined by immunocytochemistry, using an anti-C. burnetii rabbit antiserum, goat anti-rabbit immunoglobulins (DAKO Japan, Kyoto, Japan), and avidin-biotin complex (ABC; Vector Laboratories, Burlingame, Calif.), as described elsewhere (4). The number of C. burnetii-positive cells in a section was scored as follows: none, −; a few cells in a separate part, +; several cells assembled in a specific part, ++; and cells throughout the section, +++.

Serology.

Immunoglobulin G antibodies to phase I and II C. burnetii from C.B-17 and A/J mice were detected by an indirect immunofluorescence test (K. K. Htwe, K. Amano, Y. Sugiyama, K. Yagami, N. Minamoto, A. Hashimoto, T. Yamaguchi, H. Fukushi, and K. Hirai, Vet. Rec. 131:490, 1992) to determine whether the mice were infected. The serology of the SCID mice was not examined.

PCR.

DNA was extracted from liver and spleen homogenates using a DNA extraction kit, SepaGene (Sanko Junyaku Co., Tokyo, Japan). The com1 gene fragment of C. burnetii was amplified by nested PCR using the primers OMP1-OMP2 and OMP3-OMP4 (30). To avoid false positives, DNA extraction and PCR were performed carefully according to guidelines described previously (14).

Statistical analysis.

Differences between organ weights in control and infected mice were determined by Student's t test or Welch's t test following an F test. P values of <0.05 were regarded as significant.

RESULTS

Clinical signs and gross findings in SCID and immunocompetent mice.

All the SCID mice infected with 10 TCID50 of C. burnetii showed the same symptoms and died. The onset and duration of the clinical signs were as follows: 7 days postinoculation (p.i.), ruffled fur; 9 to 13 days p.i., hunchback appearance and inactivity; 27 to 31 days p.i., lethargy. The onset of a hunchback appearance and inactivity correlated with loss of body weight. Body weight continued to decline until death (Fig. 1). The survival period was 33 ± 2.5 days. None of the C.B-17 or A/J mice showed any clinical signs or died. The relative body weights of C.B-17 mice and A/J mice that were infected with 10 TCID50 of C. burnetii were similar to those of the control mice.

FIG. 1.

FIG. 1.

Weight changes of SCID mice inoculated with C. burnetii (solid circles) and PBS (open circles). A significant difference (P < 0.005) between infected and control mice was found 10 days p.i. Relative body weight is the body weight on a particular day divided by the body weight on the day of inoculation. Points represent means, error bars indicate standard deviations, and † indicates death of the mouse.

Hepatosplenomegaly was prominent in the SCID mice (Table 1), and the spleen had a pale color while the liver had necrotic foci. The A/J mice showed mild hepatosplenomegaly, whereas the C.B-17 mice showed only mild splenomegaly. In the C.B-17 and A/J mice, the liver did not have necrotic foci and the color of the spleen was normal.

TABLE 1.

Liver and spleen weights in mice inoculated with 10 TCID50 of C. burnetii or PBS

Organ Weighta
SCID mice
C.B-17 mice
A/J mice
C. burnetii PBS C. burnetii PBS C. burnetii PBS
Liver 1.81 ± 0.14b 0.85 ± 0.04 1.06 ± 0.12 1.16 ± 0.10 1.03 ± 0.11b 0.83 ± 0.06
Spleen 1.01 ± 0.09b 0.03 ± 0.01 0.17 ± 0.03b 0.10 ± 0.02 0.17 ± 0.05b 0.07 ± 0.02
a

Mean ± standard deviation (grams).

b

Significantly different (P < 0.05) from control mice.

None of the control mice showed any clinical signs or died, and no gross findings were detected.

Characteristic lesions with C. burnetii organisms in SCID mice.

The lesions in SCID mice infected with 10 TCID50 of C. burnetii were much more severe than the lesions in immunocompetent mice infected with 10 TCID50 of C. burnetii (Table 2). The most characteristic and common feature observed in the lesions of SCID mice was severe cell infiltration. Almost all infiltrated cells were morphologically macrophages, and some were neutrophils. These macrophages were dilated, giving a vacuolated appearance, and were densely packed with basophilic granules, which varied from coarse to fine and were present in several extra- and intracellular forms. Immunocytochemistry revealed that these granules were C. burnetii organisms.

TABLE 2.

Lesions and immunolocalization in mice inoculated with 10 TCID50 of C. burnetii

Organ SCID mice
C.B-17 and A/J micea
Lesion C. burnetiib Lesion C. burnetii
Heart Pancarditis; vacuolated macrophage infiltration, particularly severe in pericardium; focal calcification ++ None
Kidney Glomerulonephritis; confluence of macrophages in glomeruli and pelvis ++ None
Spleen Severe splenitis; diffuse replacement by macrophages; many vacuoles +++ Focal granulomas
Liver Severe hepatitis; diffuse replacement by macrophages; denatured and withered hepatocytes; many vacuoles; megakaryocytes +++ Focal granulomas
Lung Severe interstitial pneumonia; macrophage infiltration, particularly around the vessels +++ Minimal interstitial pneumoniac
a

There was no noticeable difference between the two mouse strains.

b

C. burnetii detection by immunocytochemistry. −, no immunopositive cells in the section; ++, immunopositive cells in a certain part of the section; +++, immunopositive cells throughout section.

c

3 of 6 C.B-17 mice and 3 of 5 A/J mice.

The hearts had severe infiltration of vacuolated macrophages in the epicardium and endocardium, including the valvular part. Focal calcification, evidence of chronic lesions, was observed in the epicardium and myocardium (Fig. 2A). Vacuolated macrophages were also found in the myocardium (Fig. 2B). In the kidney, the glomeruli were typically infiltrated with vacuolated macrophages (Fig. 2C), and the proximal tubules exhibited hyaline degeneration.

FIG.2.

FIG.2.

Heart (A and B) and kidney (C) sections from SCID mouse infected with C. burnetii. (A) Calcifications were observed in severely infiltrated lesions (arrows). There was macrophage infiltration in the epicardium (EP) and myocardium (MC). The macrophages were expanded and packed with granules (arrowheads). Hematoxylin and eosin staining; magnification, ×200. (B) C. burnetii antigens were detected as brown granules (arrowheads). ABC method; magnification, ×400. EN, endocardium; V, ventricle. (C) C. burnetii antigen-positive cells were characteristic in glomeruli (arrowheads). ABC method; magnification, ×200.

The lungs, spleen, and liver, which are the general target organs of C. burnetii in experimental animals, had severe lesions and many C. burnetii organisms. In the lungs, cells accumulated in intra-alveolar septi, stroma adjacent to airways, or venules (Fig. 3, top). The lumens contained no exudate. The spleen and liver did not retain their original structures due to bursting with macrophages and numerous vacuoles, which were probably the remains of necrotic cells. The margins of vacuoles were strongly immunopositive (Fig. 3, middle and bottom). C. burnetii organisms were also present within the hepatocytes (Fig. 3, middle). The liver also had some sporadic microabscesses, mainly containing macrophages, neutrophils, or lymphocytes. Additionally, the liver exhibited mild extramedullary hematopoiesis and contained a few megakaryocytes. Neither granulomas nor fibroblasts were found in any organs of the SCID mice.

FIG.3.

FIG.3.

Immunocytochemistry of the lung (top), liver (middle), and spleen (bottom) of SCID mouse infected with C. burnetii. C. burnetii antigens were detected as brown granules. (Top) C. burnetii antigen-positive cells infiltrated particularly in the stroma adjacent to a bronchiole (BR). AL, alveolus. (Middle) C. burnetii antigens were also found in hepatocytes (arrowheads). (Middle and bottom) The margins of vacuoles were immunopositive (arrows). ABC method; magnification, ×200.

The spleens of the control SCID mice, which originally lacked characteristic lymphoid follicles due to the absence of T and B lymphocytes, were somewhat smaller than those of the immunocompetent mice. No significant lesions were found in the control SCID mice.

General lesions in immunocompetent mice.

The lesions of immunocompetent C.B-17 and A/J mice infected with 10 TCID50 of C. burnetii were mild (Table 2) and were probably residual lesions, as reported elsewhere (3). The lesions of these two mouse strains were not noticeably different. A few small granulomas characterized by unexpanded macrophages, lymphocytes, or neutrophils were observed in the spleen, liver, and lungs. No lesions were observed in the heart or kidney. No significant lesions were found in control immunocompetent mice. Sections from both C. burnetii-inoculated and control immunocompetent mice were immunocytochemically negative and did not show nonspecific binding of ABC.

In the mice infected with 10 TCID50 of C. burnetii, the antibody titers to phase I and II C. burnetii ranged from 1:256 to 1:1,024 and from 1:512 to 1:1,024, respectively, and were equivalent in the two mouse strains. The livers and spleens of the mice were PCR positive. No C. burnetii-specific antibodies or C. burnetii DNA was detected in the control mice.

Dose responses in SCID and immunocompetent mice.

To determine the LD50 and to observe the dose response in SCID mice, graded doses of C. burnetii (104 to 10−5 TCID50) were administered. All SCID mice that died in this experiment demonstrated clinical symptoms in the same progression and died within 60 days. The mice that died included all the ones that were given 105 to 10−2 TCID50, four of six that were given 10−3 to 10−4 TCID50, and one of six that were given 10−5 TCID50 (Table 3). None of the diseased mice recovered. The LD50 of C. burnetii in the SCID mouse was <10−4 TCID50. Both the latent period (data not shown) and the survival period were inversely proportional to the inoculum size. Hepatosplenomegaly was observed in the dead SCID mice and was proportional to the survival period, but not to the inoculum size. Among the C.B-17 mice, only those receiving 104 and 103 TCID50 showed ruffled fur, hunchback appearance, inactivity, and body weight loss, but they recovered within 15 days p.i. None of the C.B-17 mice died. Splenomegaly, which was proportional to the inoculum size, was observed in mice given 104 to 10−3 TCID50. Hepatomegaly was observed only in mice administered 104 and 103 TCID50.

TABLE 3.

Survival, relative body weights, and organ weights of SCID mice infected with C. burnetii

Inoculum size (TCID50/0.5 ml) Mouse mortality (%) Survival period (days)a Relative body weight of dead micea Organ weight (mg) of dead micea
Liver Spleen
104 6/6 (100) 25.8 ± 1.7 0.73 ± 0.03 1,606 ± 250 467 ± 111
103 5/5 (100) 28.8 ± 2.6 0.78 ± 0.06 1,457 ± 165 629 ± 165
102 6/6 (100) 32.3 ± 0.5 0.81 ± 0.03 1,586 ± 135 806 ± 118
10 6/6 (100) 34.8 ± 0.8 0.85 ± 0.04 1,781 ± 188 999 ± 950
1 6/6 (100) 37.3 ± 2.3 0.86 ± 0.05 1,696 ± 293 1,018 ± 144
10−1 6/6 (100) 36.3 ± 1.6 0.90 ± 0.04 2,000 ± 144 1,150 ± 211
10−2 6/6 (100) 37.6 ± 0.8 0.89 ± 0.04 1,783 ± 132 1,107 ± 238
10−3 4/6 (66.6) 41.0 ± 2.9 0.91 ± 0.05 2,131 ± 276 1,151 ± 163
10−4 4/6 (66.6) 43.0 ± 2.5 0.94 ± 0.02 2,144 ± 193 1,251 ± 290
10−5 1/6 (16.6) 47b 0.89b 1,424b 1,306b
PBS (control) 0/6 (0) 60c 1.29c 1,185 ± 87c 39 ± 9c
a

Mean ± standard deviation

b

Data for one mouse.

c

Data from euthanized mice.

DISCUSSION

Given equivalent inocula of C. burnetii, SCID mice became persistently ill until death, whereas immunocompetent mice became transiently ill or symptomless. The SCID mice had severe chronic lesions. These results suggest that the SCID mouse is highly susceptible to C. burnetii, and the immunodeficiency of the host enhances the severity of Q fever. This is the first report of persistent C. burnetii infection in an animal that results in severe chronic lesions and death.

The higher susceptibility of immunocompromised animals to C. burnetii has been acknowledged (26, 27), and immunosuppressed mice have been used for the study of Q fever (1, 28) and the isolation of C. burnetii (11). However, the immune state of an immunosuppressed animal is unstable, which makes it difficult to study immune reactions. Immunodeficiency has been indicated as a host factor in chronic Q fever (19, 21), and Q fever endocarditis patients have been reported to be in an unbalanced immune state (7, 23). Q fever has also been observed in patients with cancer or human immunodeficiency virus infection or undergoing immunosuppressive therapy (13, 16, 20, 21). The SCID mouse has a clear and stable immunodeficient state, so it can be an animal model for the study of Q fever in an immunodeficient host.

Infection with 10 TCID50 of C. burnetii caused death in the SCID mice, but the immunocompetent mice were asymptomatic. We concluded that the deaths of the SCID mice were due to chronic disease, as we observed that the survivability or death of mice infected with C. burnetii is determined within 2 weeks postinfection (references 3 and 25 and our unpublished data). The lesions in the SCID mice were more severe than those in the immunocompetent mice. C. burnetii replicated abundantly within macrophages in SCID mice, as revealed by immunocytochemistry. This result agrees with those of previous studies (2, 17) indicating that during infection, C. burnetii is concentrated in cells with macrophage activity. Because the SCID mouse is the key animal for the study of macrophage-dependent resistance (6), our new animal model should also help to elucidate the unexplained pathogenesis of Q fever.

The most characteristic lesions of SCID mice were observed in the heart and kidney. To our knowledge, these are the most severe chronic lesions to be reported in animals. Our present results reinforce the hypothesis that an immunocompromised state is an important factor in Q fever endocarditis (19). Heart disease developed in the SCID mouse within 2 months, whereas human chronic Q fever may take years to develop. Nevertheless, the hearts of SCID mice infected with C. burnetii share some characteristics with the hearts of humans with Q fever endocarditis: focal calcification and large macrophages containing C. burnetii organisms (22). Because the SCID mouse shows a high incidence of endocarditis without any treatment, it is a promising new animal model for Q fever endocarditis.

Glomerulonephritis has been reported as a manifestation of Q fever in humans (18, 29; M. Morovic, B. Dzelalija, S. Novakovic, S. Stankovic, and J. Dujella, Letter, Nephron 64:335, 1993). In animals, renal disease caused by C. burnetii is only a transient lesion as part of a disseminated C. burnetii infection (3). However, the pathogenesis of renal disease in SCID mice may be different from that in human Q fever cases, because renal disease in human Q fever is due to immune complexes, while the SCID mouse is unable to produce immunoglobulins. However, the SCID mouse model suggests that there is a risk of renal disease associated with C. burnetii infection in immunocompromised hosts.

The LD50 of C. burnetii in the SCID mice was at least 108 times less than that in the C.B-17 mice, none of which died after C. burnetii infection in this study. Despite the inoculum size, the SCID mice could not recover from the disease and died. The finding that hepatosplenomegaly was proportional to the survival period suggests that C. burnetii continued to proliferate in the bodies of the SCID mice. (The amount of C. burnetii in the spleen was ∼107 TCID50/g; other organs were not examined.) It has been suggested that immunosuppression can amplify the severity of Q fever (1, 21, 26, 27, 28). Our findings agree with this theory. Because the number of immunocompromised hosts is increasing with greater use of immunosuppression in modern medicine and with the spread of human immunodeficiency virus infection, an increasing number of people are at risk of acquiring Q fever.

The SCID mice in this study were probably acutely infected with C. burnetii and then experienced chronic disease. Our results support the importance of host factors in Q fever and contradict the hypothesis that certain strains of C. burnetii specifically cause acute or chronic disease. However, we cannot assume that all strains of C. burnetii have the same pathogenicity (10). We are presently investigating in more detail the distribution of C. burnetii in SCID mice and the pathogenicities of other C. burnetii isolates, which have different plasmid or gene patterns. We are also investigating the pathogenicity of C. burnetii associated with lipopolysaccharide variants during the phase variation reported earlier (12).

Acknowledgments

This work was supported by Science Research Grants numbers 07306015 and 10460140 from the Ministry of Education, Science, Sports and Culture and by Health Sciences Research grant H10-Emerg-7 on “Emerging and Re-emerging Infectious Diseases” from the Ministry of Health and Welfare of Japan.

Editor: V. J. DiRita

REFERENCES

  • 1.Atzpodien, E., W. Baumgartner, A. Artelt, and D. Thiele. 1994. Valvular endocarditis occurs as a part of a disseminated Coxiella burnetii infection in immunocompromised BALB/cJ (H-2d) mice infected with the nine mile isolate of C. burnetii. J. Infect. Dis. 170:223-226. [DOI] [PubMed] [Google Scholar]
  • 2.Baumgartner, W., and S. Bachmann. 1992. Histological and immunocytochemical characterization of Coxiella burnetii-associated lesions in the murine uterus and placenta. Infect. Immun. 60:5232-5241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Baumgartner, W., H. Dettinger, and N. Schmeer. 1993. Spread and distribution of Coxiella burnetii in C57BL/6J (H-2b) and Balb/cJ (H-2d) mice after intraperitoneal infection. J. Comp. Pathol. 108:165-184. [DOI] [PubMed] [Google Scholar]
  • 4.Baumgartner, W., H. Dettinger, N. Schmeer, and E. Hoffmeister. 1988. Evaluation of different fixatives and treatments for immunohistochemical demonstration of Coxiella burnetii in paraffin-embedded tissues. J. Clin. Microbiol. 26:2044-2047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Behrens, B., and G. Kärber. 1935. Wie sind Rehenversuche für biologishe Auswertungen am zweckmäsigsten anzuordnen? Naunyn Schmiedebergs Arch. Pharmakol. Exp. Pathol. 177:377-388. [Google Scholar]
  • 6.Bosma, G. C., R. P. Custer, and M. J. Bosma. 1983. A severe combined immunodeficiency mutation in the mouse. Nature 301:527-530. [DOI] [PubMed] [Google Scholar]
  • 7.Capo, C., F. Zugun, A. Stein, G. Tardei, H. Lepidi, D. Raoult, and J. L. Mege. 1996. Upregulation of tumor necrosis factor alpha and interleukin-1 beta in Q fever endocarditis. Infect. Immun. 64:1638-1642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dorshkind, K., G. M. Keller, R. A. Phillips, R. G. Miller, G. C. Bosma, M. O'Toole, and M. J. Bosma. 1984. Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease. J. Immunol. 132:1804-1808. [PubMed] [Google Scholar]
  • 9.Fenollar, F., P. E. Fournier, M. P. Carrieri, G. Habib, T. Messana, and D. Raoult. 2001. Risks factors and prevention of Q fever endocarditis. Clin. Infect. Dis. 33:312-316. [DOI] [PubMed] [Google Scholar]
  • 10.Hirai, K., and H. To. 1998. Advances in the understanding of Coxiella burnetii infection in Japan. J. Vet. Med. Sci. 60:781-790. [DOI] [PubMed] [Google Scholar]
  • 11.Ho, T., K. K. Htwe, N. Yamasaki, G. Q. Zhang, M. Ogawa, T. Yamaguchi, H. Fukushi, and K. Hirai. 1995. Isolation of Coxiella burnetii from dairy cattle and ticks, and some characteristics of the isolates in Japan. Microbiol. Immunol. 39:663-671. [DOI] [PubMed] [Google Scholar]
  • 12.Hotta, A., M. Kawamura, H. To, M. Andoh, T. Yamaguchi, H. Fukushi, and K. Hirai. 2002. Phase variation analysis of Coxiella burnetii during serial passage in cell culture by use of monoclonal antibodies. Infect. Immun. 70:4747-4749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kanfer, E., N. Farrag, C. Price, D. MacDonald, J. Coleman, and A. J. Barrett. 1988. Q fever following bone marrow transplantation. Bone Marrow Transplant. 3:165-166. [PubMed] [Google Scholar]
  • 14.Kwok, S., and R. Higuchi. 1989. Avoiding false positives with PCR. Nature 339:237-238. [DOI] [PubMed] [Google Scholar]
  • 15.La Scola, B., H. Lepidi, M. Maurin, and D. Raoult. 1998. A guinea pig model for Q fever endocarditis. J. Infect. Dis. 178:278-281. [DOI] [PubMed] [Google Scholar]
  • 16.Lev, B. I., A. Shachar, S. Segev, P. Weiss, and E. Rubinstein. 1988. Quiescent Q fever endocarditis exacerbated by cardiac surgery and corticosteroid therapy. Arch. Intern. Med. 148:1531-1532. [PubMed] [Google Scholar]
  • 17.Marrie, T. J., A. Stein, D. Janigan, and D. Raoult. 1996. Route of infection determines the clinical manifestations of acute Q fever. J. Infect. Dis. 173:484-487. [DOI] [PubMed] [Google Scholar]
  • 18.Perez-Fontan, M., E. Huarte, A. Tellez, A. Rodriguez-Carmona, M. L. Picazo, and J. Martinez-Ara. 1988. Glomerular nephropathy associated with chronic Q fever. Am. J. Kidney Dis. 11:298-306. [DOI] [PubMed] [Google Scholar]
  • 19.Raoult, D. 1990. Host factors in the severity of Q fever. Ann. N. Y. Acad. Sci. 590:33-38. [DOI] [PubMed] [Google Scholar]
  • 20.Raoult, D., P. Brouqui, B. Marchou, and J. A. Gastaut. 1992. Acute and chronic Q fever in patients with cancer. Clin. Infect. Dis. 14:127-130. [DOI] [PubMed] [Google Scholar]
  • 21.Raoult, D., P. Y. Levy, H. T. Dupont, C. Chicheportiche, C. Tamalet, J. A. Gastaut, and J. Salducci. 1993. Q fever and HIV infection. AIDS 7:81-86. [DOI] [PubMed] [Google Scholar]
  • 22.Raoult, D., A. Raza, and T. J. Marrie. 1990. Q fever endocarditis and other forms of chronic Q fever, p. 179-199. In T. J. Marrie (ed.), Q fever, vol. 1. The disease. CRC Press, Inc., Boca Raton, Fla.
  • 23.Sabatier, F., F. Dignat-George, J. L. Mege, C. Brunet, D. Raoult, and J. Sampol. 1997. CD4+ T-cell lymphopenia in Q fever endocarditis. Clin. Diagn. Lab. Immunol. 4:89-92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schmeer, N., W. Schmuck, W. Schneider, M. Karo, and H. Krauss. 1987. Detection of Coxiella burnetii by the immunoperoxidase technique. Zentbl. Bakteriol. Mikrobiol. Hyg. A 267:67-73. [DOI] [PubMed] [Google Scholar]
  • 25.Scott, G. H., J. C. Williams, and E. H. Stephenson. 1987. Animal models in Q fever: pathological responses of inbred mice to phase I Coxiella burnetii. J. Gen. Microbiol. 133:691-700. [DOI] [PubMed] [Google Scholar]
  • 26.Sidwell, R. W., B. D. Thorpe, and L. P. Gebhardt. 1964. Studies of latent Q fever infections. I. Effects of whole body X-irradiation upon latently infected guinea pigs, white mice and deer mice. Am. J. Hyg. 79:113-124. [PubMed] [Google Scholar]
  • 27.Sidwell, R. W., B. D. Thorpe, and L. P. Gebhardt. 1964. Studies of latent Q fever infections. II. Effects of multiple cortisone injections. Am. J. Hyg. 79:320-327. [DOI] [PubMed] [Google Scholar]
  • 28.Stein, A., H. Lepidi, J. L. Mege, T. J. Marrie, and D. Raoult. 2000. Repeated pregnancies in BALB/c mice infected with Coxiella burnetii cause disseminated infection, resulting in stillbirth and endocarditis. J. Infect. Dis. 181:188-194. [DOI] [PubMed] [Google Scholar]
  • 29.Uff, J. S., and D. J. Evans. 1977. Mesangio-capillary glomerulonephritis associated with Q-fever endocarditis. Histopathology 1:463-472. [DOI] [PubMed] [Google Scholar]
  • 30.Zhang, G. Q., S. V. Nguyen, H. To, M. Ogawa, A. Hotta, T. Yamaguchi, H. J. Kim, H. Fukushi, and K. Hirai. 1998. Clinical evaluation of a new PCR assay for detection of Coxiella burnetii in human serum samples. J. Clin. Microbiol. 36:77-80. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES